These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 20956940)

  • 1. Epigenetic inactivation of the RASSF10 candidate tumor suppressor gene is a frequent and an early event in gliomagenesis.
    Hill VK; Underhill-Day N; Krex D; Robel K; Sangan CB; Summersgill HR; Morris M; Gentle D; Chalmers AD; Maher ER; Latif F
    Oncogene; 2011 Feb; 30(8):978-89. PubMed ID: 20956940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas.
    Chou AP; Chowdhury R; Li S; Chen W; Kim AJ; Piccioni DE; Selfridge JM; Mody RR; Chang S; Lalezari S; Lin J; Sanchez DE; Wilson RW; Garrett MC; Harry B; Mottahedeh J; Nghiemphu PL; Kornblum HI; Mischel PS; Prins RM; Yong WH; Cloughesy T; Nelson SF; Liau LM; Lai A
    J Natl Cancer Inst; 2012 Oct; 104(19):1458-69. PubMed ID: 22945948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas.
    Juratli TA; Kirsch M; Geiger K; Klink B; Leipnitz E; Pinzer T; Soucek S; Schrock E; Schackert G; Krex D
    J Neurooncol; 2012 Dec; 110(3):325-33. PubMed ID: 23015095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias.
    Hesson LB; Dunwell TL; Cooper WN; Catchpoole D; Brini AT; Chiaramonte R; Griffiths M; Chalmers AD; Maher ER; Latif F
    Mol Cancer; 2009 Jul; 8():42. PubMed ID: 19570220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stability of the CpG island methylator phenotype during glioma progression and identification of methylated loci in secondary glioblastomas.
    Hill VK; Shinawi T; Ricketts CJ; Krex D; Schackert G; Bauer J; Wei W; Cruickshank G; Maher ER; Latif F
    BMC Cancer; 2014 Jul; 14():506. PubMed ID: 25012071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic down regulation of RASSF10 and its possible clinical implication in prostate carcinoma.
    Dansranjavin T; Wagenlehner F; Gattenloehner S; Steger K; Weidner W; Dammann R; Schagdarsurengin U
    Prostate; 2012 Oct; 72(14):1550-8. PubMed ID: 22415519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RASSF10 promoter hypermethylation is frequent in malignant melanoma of the skin but uncommon in nevus cell nevi.
    Helmbold P; Richter AM; Walesch S; Skorokhod A; Marsch WCh; Enk A; Dammann RH
    J Invest Dermatol; 2012 Mar; 132(3 Pt 1):687-94. PubMed ID: 22113481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequent epigenetic inactivation of RASSF10 in thyroid cancer.
    Schagdarsurengin U; Richter AM; Wöhler C; Dammann RH
    Epigenetics; 2009 Nov; 4(8):571-6. PubMed ID: 19934646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RASSF10 is frequently epigenetically inactivated in kidney cancer and its knockout promotes neoplasia in cancer prone mice.
    Richter AM; Woods ML; Küster MM; Walesch SK; Braun T; Boettger T; Dammann RH
    Oncogene; 2020 Apr; 39(15):3114-3127. PubMed ID: 32047266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequent promoter hypermethylation and transcriptional downregulation of the NDRG2 gene at 14q11.2 in primary glioblastoma.
    Tepel M; Roerig P; Wolter M; Gutmann DH; Perry A; Reifenberger G; Riemenschneider MJ
    Int J Cancer; 2008 Nov; 123(9):2080-6. PubMed ID: 18709645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
    Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
    Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.
    Sanson M; Marie Y; Paris S; Idbaih A; Laffaire J; Ducray F; El Hallani S; Boisselier B; Mokhtari K; Hoang-Xuan K; Delattre JY
    J Clin Oncol; 2009 Sep; 27(25):4150-4. PubMed ID: 19636000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential gene methylation in paired glioblastomas suggests a role of immune response pathways in tumor progression.
    Alentorn A; Durán-Peña A; Malousi A; Marie Y; Mokhtari K; Sanson M; Hoang-Xuan K; Delattre JY; Idbaih A; Vecht C
    J Neurooncol; 2015 Sep; 124(3):385-92. PubMed ID: 26224161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RASSF10 is an epigenetically silenced tumor suppressor in gastric cancer.
    Li Z; Chang X; Dai D; Deng P; Sun Q
    Oncol Rep; 2014 Apr; 31(4):1661-8. PubMed ID: 24573726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA hypermethylation of tumor suppressor genes RASSF6 and RASSF10 as independent prognostic factors in adult acute lymphoblastic leukemia.
    Younesian S; Shahkarami S; Ghaffari P; Alizadeh S; Mehrasa R; Ghavamzadeh A; Ghaffari SH
    Leuk Res; 2017 Oct; 61():33-38. PubMed ID: 28869817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RASSF10 is an epigenetically inactivated tumor suppressor and independent prognostic factor in hepatocellular carcinoma.
    Wang F; Feng Y; Li P; Wang K; Feng L; Liu YF; Huang H; Guo YB; Mao QS; Xue WJ
    Oncotarget; 2016 Jan; 7(4):4279-97. PubMed ID: 26701853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma.
    Carrillo JA; Lai A; Nghiemphu PL; Kim HJ; Phillips HS; Kharbanda S; Moftakhar P; Lalaezari S; Yong W; Ellingson BM; Cloughesy TF; Pope WB
    AJNR Am J Neuroradiol; 2012 Aug; 33(7):1349-55. PubMed ID: 22322613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RASSF10 is epigenetically silenced and functions as a tumor suppressor in gastric cancer.
    Wei Z; Chen X; Chen J; Wang W; Xu X; Cai Q
    Biochem Biophys Res Commun; 2013 Mar; 432(4):632-7. PubMed ID: 23428420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation.
    Kessler T; Sahm F; Sadik A; Stichel D; Hertenstein A; Reifenberger G; Zacher A; Sabel M; Tabatabai G; Steinbach J; Sure U; Krex D; Grosu AL; Bewerunge-Hudler M; Jones D; Pfister SM; Weller M; Opitz C; Bendszus M; von Deimling A; Platten M; Wick W
    Neuro Oncol; 2018 Feb; 20(3):367-379. PubMed ID: 29016808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ras association domain family member 10 suppresses gastric cancer growth by cooperating with GSTP1 to regulate JNK/c-Jun/AP-1 pathway.
    Li X; Liang Q; Liu W; Zhang N; Xu L; Zhang X; Zhang J; Sung JJ; Yu J
    Oncogene; 2016 May; 35(19):2453-64. PubMed ID: 26279301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.